nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—UGT1A9—Irinotecan—pancreatic cancer	0.114	0.154	CbGbCtD
Canagliflozin—ORM1—Erlotinib—pancreatic cancer	0.0934	0.126	CbGbCtD
Canagliflozin—ABCC2—Tamoxifen—pancreatic cancer	0.0742	0.0997	CbGbCtD
Canagliflozin—ABCC2—Irinotecan—pancreatic cancer	0.0569	0.0766	CbGbCtD
Canagliflozin—ABCC2—Docetaxel—pancreatic cancer	0.0417	0.0561	CbGbCtD
Canagliflozin—ABCC2—Sunitinib—pancreatic cancer	0.0415	0.0558	CbGbCtD
Canagliflozin—ALB—Erlotinib—pancreatic cancer	0.0393	0.0528	CbGbCtD
Canagliflozin—ALB—Irinotecan—pancreatic cancer	0.0355	0.0477	CbGbCtD
Canagliflozin—ALB—Fluorouracil—pancreatic cancer	0.0341	0.0458	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—pancreatic cancer	0.0311	0.0418	CbGbCtD
Canagliflozin—ABCB1—Tamoxifen—pancreatic cancer	0.0242	0.0325	CbGbCtD
Canagliflozin—ABCB1—Gemcitabine—pancreatic cancer	0.0208	0.028	CbGbCtD
Canagliflozin—ABCB1—Erlotinib—pancreatic cancer	0.0206	0.0276	CbGbCtD
Canagliflozin—ABCB1—Irinotecan—pancreatic cancer	0.0186	0.025	CbGbCtD
Canagliflozin—CYP3A4—Tamoxifen—pancreatic cancer	0.0145	0.0195	CbGbCtD
Canagliflozin—ABCB1—Docetaxel—pancreatic cancer	0.0136	0.0183	CbGbCtD
Canagliflozin—ABCB1—Sunitinib—pancreatic cancer	0.0135	0.0182	CbGbCtD
Canagliflozin—ABCC2—bile duct—pancreatic cancer	0.0126	0.254	CbGeAlD
Canagliflozin—CYP3A4—Erlotinib—pancreatic cancer	0.0123	0.0166	CbGbCtD
Canagliflozin—ORM1—bile—pancreatic cancer	0.0118	0.238	CbGeAlD
Canagliflozin—CYP3A4—Irinotecan—pancreatic cancer	0.0111	0.015	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—pancreatic cancer	0.0101	0.0136	CbGbCtD
Canagliflozin—ABCC2—bile—pancreatic cancer	0.0097	0.195	CbGeAlD
Canagliflozin—CYP3A4—Docetaxel—pancreatic cancer	0.00815	0.011	CbGbCtD
Canagliflozin—CYP3A4—Sunitinib—pancreatic cancer	0.00811	0.0109	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—pancreatic cancer	0.00608	0.00817	CbGbCtD
Canagliflozin—SLC5A1—digestive system—pancreatic cancer	0.00389	0.0784	CbGeAlD
Canagliflozin—ORM1—gall bladder—pancreatic cancer	0.00328	0.066	CbGeAlD
Canagliflozin—ALB—gall bladder—pancreatic cancer	0.00287	0.0578	CbGeAlD
Canagliflozin—UGT1A9—digestive system—pancreatic cancer	0.00245	0.0493	CbGeAlD
Canagliflozin—ABCC2—digestive system—pancreatic cancer	0.00106	0.0213	CbGeAlD
Canagliflozin—Urinary tract disorder—Erlotinib—pancreatic cancer	0.000638	0.00412	CcSEcCtD
Canagliflozin—ABCB1—islet of Langerhans—pancreatic cancer	0.000635	0.0128	CbGeAlD
Canagliflozin—Urethral disorder—Erlotinib—pancreatic cancer	0.000633	0.00409	CcSEcCtD
Canagliflozin—Blood creatinine increased—Irinotecan—pancreatic cancer	0.000624	0.00403	CcSEcCtD
Canagliflozin—Dehydration—Irinotecan—pancreatic cancer	0.000619	0.004	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Irinotecan—pancreatic cancer	0.000608	0.00393	CcSEcCtD
Canagliflozin—Blood creatinine increased—Gemcitabine—pancreatic cancer	0.000607	0.00393	CcSEcCtD
Canagliflozin—Urinary tract infection—Sunitinib—pancreatic cancer	0.000605	0.00391	CcSEcCtD
Canagliflozin—Erythema—Tamoxifen—pancreatic cancer	0.000568	0.00367	CcSEcCtD
Canagliflozin—Pancreatitis—Irinotecan—pancreatic cancer	0.000564	0.00365	CcSEcCtD
Canagliflozin—Malnutrition—Erlotinib—pancreatic cancer	0.000562	0.00364	CcSEcCtD
Canagliflozin—Erythema—Erlotinib—pancreatic cancer	0.000562	0.00364	CcSEcCtD
Canagliflozin—Rash erythematous—Epirubicin—pancreatic cancer	0.000558	0.00361	CcSEcCtD
Canagliflozin—Urinary tract disorder—Sunitinib—pancreatic cancer	0.000552	0.00357	CcSEcCtD
Canagliflozin—Urethral disorder—Sunitinib—pancreatic cancer	0.000548	0.00354	CcSEcCtD
Canagliflozin—CYP3A4—digestive system—pancreatic cancer	0.000538	0.0108	CbGeAlD
Canagliflozin—Rash pustular—Epirubicin—pancreatic cancer	0.000536	0.00347	CcSEcCtD
Canagliflozin—Angioedema—Tamoxifen—pancreatic cancer	0.000519	0.00336	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—pancreatic cancer	0.000517	0.00334	CcSEcCtD
Canagliflozin—Angiopathy—Sunitinib—pancreatic cancer	0.000507	0.00328	CcSEcCtD
Canagliflozin—Syncope—Erlotinib—pancreatic cancer	0.000504	0.00326	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Fluorouracil—pancreatic cancer	0.000503	0.00325	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—pancreatic cancer	0.000496	0.00321	CcSEcCtD
Canagliflozin—Loss of consciousness—Erlotinib—pancreatic cancer	0.000494	0.00319	CcSEcCtD
Canagliflozin—Erythema—Sunitinib—pancreatic cancer	0.000487	0.00315	CcSEcCtD
Canagliflozin—Malnutrition—Sunitinib—pancreatic cancer	0.000487	0.00315	CcSEcCtD
Canagliflozin—Urinary tract infection—Fluorouracil—pancreatic cancer	0.000478	0.00309	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.000475	0.00307	CcSEcCtD
Canagliflozin—Dry mouth—Tamoxifen—pancreatic cancer	0.000473	0.00306	CcSEcCtD
Canagliflozin—Nocturia—Epirubicin—pancreatic cancer	0.000461	0.00298	CcSEcCtD
Canagliflozin—Infection—Tamoxifen—pancreatic cancer	0.000461	0.00298	CcSEcCtD
Canagliflozin—Infection—Erlotinib—pancreatic cancer	0.000456	0.00295	CcSEcCtD
Canagliflozin—Shock—Erlotinib—pancreatic cancer	0.000451	0.00292	CcSEcCtD
Canagliflozin—Nervous system disorder—Erlotinib—pancreatic cancer	0.00045	0.00291	CcSEcCtD
Canagliflozin—ABCB1—pancreas—pancreatic cancer	0.000446	0.00898	CbGeAlD
Canagliflozin—Skin disorder—Erlotinib—pancreatic cancer	0.000446	0.00288	CcSEcCtD
Canagliflozin—Angioedema—Sunitinib—pancreatic cancer	0.000445	0.00288	CcSEcCtD
Canagliflozin—Urinary tract disorder—Gemcitabine—pancreatic cancer	0.000443	0.00286	CcSEcCtD
Canagliflozin—Urethral disorder—Gemcitabine—pancreatic cancer	0.00044	0.00284	CcSEcCtD
Canagliflozin—Dehydration—Docetaxel—pancreatic cancer	0.000428	0.00277	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—pancreatic cancer	0.000426	0.00276	CcSEcCtD
Canagliflozin—Convulsion—Sunitinib—pancreatic cancer	0.000422	0.00273	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00042	0.00272	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—pancreatic cancer	0.00042	0.00272	CcSEcCtD
Canagliflozin—Angiopathy—Irinotecan—pancreatic cancer	0.000418	0.0027	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—pancreatic cancer	0.000418	0.0027	CcSEcCtD
Canagliflozin—Breast disorder—Docetaxel—pancreatic cancer	0.000416	0.00269	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—pancreatic cancer	0.000413	0.00267	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000411	0.00266	CcSEcCtD
Canagliflozin—Angiopathy—Gemcitabine—pancreatic cancer	0.000407	0.00263	CcSEcCtD
Canagliflozin—Dry mouth—Sunitinib—pancreatic cancer	0.000405	0.00262	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—pancreatic cancer	0.000404	0.00261	CcSEcCtD
Canagliflozin—Vaginal infection—Epirubicin—pancreatic cancer	0.000404	0.00261	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.0004	0.00259	CcSEcCtD
Canagliflozin—Fatigue—Tamoxifen—pancreatic cancer	0.0004	0.00259	CcSEcCtD
Canagliflozin—Constipation—Tamoxifen—pancreatic cancer	0.000397	0.00256	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000396	0.00256	CcSEcCtD
Canagliflozin—Fatigue—Erlotinib—pancreatic cancer	0.000396	0.00256	CcSEcCtD
Canagliflozin—Infection—Sunitinib—pancreatic cancer	0.000395	0.00255	CcSEcCtD
Canagliflozin—Constipation—Erlotinib—pancreatic cancer	0.000392	0.00254	CcSEcCtD
Canagliflozin—Shock—Sunitinib—pancreatic cancer	0.000391	0.00253	CcSEcCtD
Canagliflozin—Erythema—Gemcitabine—pancreatic cancer	0.00039	0.00252	CcSEcCtD
Canagliflozin—Nervous system disorder—Sunitinib—pancreatic cancer	0.000389	0.00252	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—pancreatic cancer	0.000389	0.00251	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—pancreatic cancer	0.000389	0.00251	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—pancreatic cancer	0.000387	0.0025	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—pancreatic cancer	0.000386	0.0025	CcSEcCtD
Canagliflozin—Skin disorder—Sunitinib—pancreatic cancer	0.000386	0.00249	CcSEcCtD
Canagliflozin—Erythema—Fluorouracil—pancreatic cancer	0.000384	0.00248	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—pancreatic cancer	0.000382	0.00247	CcSEcCtD
Canagliflozin—ABCB1—digestive system—pancreatic cancer	0.000381	0.00767	CbGeAlD
Canagliflozin—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000379	0.00245	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000375	0.00243	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—pancreatic cancer	0.000373	0.00242	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—pancreatic cancer	0.000373	0.00242	CcSEcCtD
Canagliflozin—Urticaria—Tamoxifen—pancreatic cancer	0.000368	0.00238	CcSEcCtD
Canagliflozin—Abdominal pain—Tamoxifen—pancreatic cancer	0.000367	0.00237	CcSEcCtD
Canagliflozin—Abdominal pain—Erlotinib—pancreatic cancer	0.000363	0.00235	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—pancreatic cancer	0.00036	0.00233	CcSEcCtD
Canagliflozin—Syncope—Irinotecan—pancreatic cancer	0.000359	0.00232	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—pancreatic cancer	0.000358	0.00231	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—pancreatic cancer	0.000357	0.00231	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—pancreatic cancer	0.000353	0.00229	CcSEcCtD
Canagliflozin—Loss of consciousness—Irinotecan—pancreatic cancer	0.000352	0.00228	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000343	0.00222	CcSEcCtD
Canagliflozin—Fatigue—Sunitinib—pancreatic cancer	0.000342	0.00221	CcSEcCtD
Canagliflozin—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000342	0.00221	CcSEcCtD
Canagliflozin—Constipation—Sunitinib—pancreatic cancer	0.00034	0.0022	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—pancreatic cancer	0.000336	0.00217	CcSEcCtD
Canagliflozin—Asthenia—Tamoxifen—pancreatic cancer	0.000333	0.00215	CcSEcCtD
Canagliflozin—Convulsion—Fluorouracil—pancreatic cancer	0.000333	0.00215	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.00033	0.00213	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00033	0.00213	CcSEcCtD
Canagliflozin—Asthenia—Erlotinib—pancreatic cancer	0.000329	0.00213	CcSEcCtD
Canagliflozin—Pruritus—Tamoxifen—pancreatic cancer	0.000328	0.00212	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—pancreatic cancer	0.000327	0.00211	CcSEcCtD
Canagliflozin—Infection—Irinotecan—pancreatic cancer	0.000325	0.0021	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000325	0.0021	CcSEcCtD
Canagliflozin—Pruritus—Erlotinib—pancreatic cancer	0.000325	0.0021	CcSEcCtD
Canagliflozin—Shock—Irinotecan—pancreatic cancer	0.000322	0.00208	CcSEcCtD
Canagliflozin—Nervous system disorder—Irinotecan—pancreatic cancer	0.000321	0.00207	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—pancreatic cancer	0.000318	0.00206	CcSEcCtD
Canagliflozin—Infection—Gemcitabine—pancreatic cancer	0.000317	0.00205	CcSEcCtD
Canagliflozin—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000314	0.00203	CcSEcCtD
Canagliflozin—Abdominal pain—Sunitinib—pancreatic cancer	0.000314	0.00203	CcSEcCtD
Canagliflozin—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000313	0.00202	CcSEcCtD
Canagliflozin—Urethral disorder—Docetaxel—pancreatic cancer	0.000312	0.00202	CcSEcCtD
Canagliflozin—Infection—Fluorouracil—pancreatic cancer	0.000311	0.00201	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—pancreatic cancer	0.000311	0.00201	CcSEcCtD
Canagliflozin—Skin disorder—Gemcitabine—pancreatic cancer	0.00031	0.002	CcSEcCtD
Canagliflozin—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000307	0.00199	CcSEcCtD
Canagliflozin—Dizziness—Tamoxifen—pancreatic cancer	0.000307	0.00198	CcSEcCtD
Canagliflozin—Hypotension—Irinotecan—pancreatic cancer	0.000306	0.00198	CcSEcCtD
Canagliflozin—Dizziness—Erlotinib—pancreatic cancer	0.000303	0.00196	CcSEcCtD
Canagliflozin—Hypotension—Gemcitabine—pancreatic cancer	0.000298	0.00193	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000294	0.0019	CcSEcCtD
Canagliflozin—Hypotension—Fluorouracil—pancreatic cancer	0.000293	0.00189	CcSEcCtD
Canagliflozin—Hypersensitivity—Sunitinib—pancreatic cancer	0.000293	0.00189	CcSEcCtD
Canagliflozin—Rash—Tamoxifen—pancreatic cancer	0.000292	0.00189	CcSEcCtD
Canagliflozin—Dermatitis—Tamoxifen—pancreatic cancer	0.000292	0.00189	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000291	0.00188	CcSEcCtD
Canagliflozin—Rash—Erlotinib—pancreatic cancer	0.000289	0.00187	CcSEcCtD
Canagliflozin—Dermatitis—Erlotinib—pancreatic cancer	0.000289	0.00187	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—pancreatic cancer	0.000289	0.00187	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—pancreatic cancer	0.000289	0.00187	CcSEcCtD
Canagliflozin—Asthenia—Sunitinib—pancreatic cancer	0.000285	0.00184	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000283	0.00183	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000282	0.00183	CcSEcCtD
Canagliflozin—Fatigue—Irinotecan—pancreatic cancer	0.000282	0.00182	CcSEcCtD
Canagliflozin—Pruritus—Sunitinib—pancreatic cancer	0.000281	0.00182	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—pancreatic cancer	0.00028	0.00181	CcSEcCtD
Canagliflozin—Constipation—Irinotecan—pancreatic cancer	0.00028	0.00181	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—pancreatic cancer	0.000277	0.00179	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—pancreatic cancer	0.000277	0.00179	CcSEcCtD
Canagliflozin—Nausea—Tamoxifen—pancreatic cancer	0.000275	0.00178	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000275	0.00178	CcSEcCtD
Canagliflozin—Fatigue—Gemcitabine—pancreatic cancer	0.000275	0.00178	CcSEcCtD
Canagliflozin—Constipation—Gemcitabine—pancreatic cancer	0.000273	0.00176	CcSEcCtD
Canagliflozin—Nausea—Erlotinib—pancreatic cancer	0.000273	0.00176	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000271	0.00175	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000269	0.00174	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000268	0.00173	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—pancreatic cancer	0.000267	0.00173	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—pancreatic cancer	0.000263	0.0017	CcSEcCtD
Canagliflozin—Dizziness—Sunitinib—pancreatic cancer	0.000263	0.0017	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000262	0.0017	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—pancreatic cancer	0.000259	0.00168	CcSEcCtD
Canagliflozin—Abdominal pain—Irinotecan—pancreatic cancer	0.000259	0.00167	CcSEcCtD
Canagliflozin—Rash—Sunitinib—pancreatic cancer	0.00025	0.00162	CcSEcCtD
Canagliflozin—Dermatitis—Sunitinib—pancreatic cancer	0.00025	0.00162	CcSEcCtD
Canagliflozin—Urticaria—Fluorouracil—pancreatic cancer	0.000249	0.00161	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—pancreatic cancer	0.000248	0.00161	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—pancreatic cancer	0.000248	0.0016	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000245	0.00158	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—pancreatic cancer	0.000244	0.00157	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—pancreatic cancer	0.000243	0.00157	CcSEcCtD
Canagliflozin—Hypersensitivity—Irinotecan—pancreatic cancer	0.000241	0.00156	CcSEcCtD
Canagliflozin—Convulsion—Docetaxel—pancreatic cancer	0.00024	0.00155	CcSEcCtD
Canagliflozin—Nausea—Sunitinib—pancreatic cancer	0.000236	0.00153	CcSEcCtD
Canagliflozin—Asthenia—Irinotecan—pancreatic cancer	0.000235	0.00152	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000234	0.00152	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—pancreatic cancer	0.000232	0.0015	CcSEcCtD
Canagliflozin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000231	0.00149	CcSEcCtD
Canagliflozin—Dry mouth—Docetaxel—pancreatic cancer	0.000231	0.00149	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—pancreatic cancer	0.000229	0.00148	CcSEcCtD
Canagliflozin—Asthenia—Gemcitabine—pancreatic cancer	0.000229	0.00148	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000227	0.00146	CcSEcCtD
Canagliflozin—Pruritus—Gemcitabine—pancreatic cancer	0.000225	0.00146	CcSEcCtD
Canagliflozin—Infection—Docetaxel—pancreatic cancer	0.000225	0.00145	CcSEcCtD
Canagliflozin—Shock—Docetaxel—pancreatic cancer	0.000222	0.00144	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—pancreatic cancer	0.000222	0.00143	CcSEcCtD
Canagliflozin—Pruritus—Fluorouracil—pancreatic cancer	0.000222	0.00143	CcSEcCtD
Canagliflozin—Skin disorder—Docetaxel—pancreatic cancer	0.00022	0.00142	CcSEcCtD
Canagliflozin—Dizziness—Irinotecan—pancreatic cancer	0.000216	0.0014	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000215	0.00139	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000212	0.00137	CcSEcCtD
Canagliflozin—Hypotension—Docetaxel—pancreatic cancer	0.000211	0.00137	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—pancreatic cancer	0.00021	0.00136	CcSEcCtD
Canagliflozin—Dizziness—Fluorouracil—pancreatic cancer	0.000207	0.00134	CcSEcCtD
Canagliflozin—Rash—Irinotecan—pancreatic cancer	0.000206	0.00133	CcSEcCtD
Canagliflozin—Dermatitis—Irinotecan—pancreatic cancer	0.000206	0.00133	CcSEcCtD
Canagliflozin—Rash—Gemcitabine—pancreatic cancer	0.000201	0.0013	CcSEcCtD
Canagliflozin—Dermatitis—Gemcitabine—pancreatic cancer	0.000201	0.0013	CcSEcCtD
Canagliflozin—Rash—Fluorouracil—pancreatic cancer	0.000198	0.00128	CcSEcCtD
Canagliflozin—Dermatitis—Fluorouracil—pancreatic cancer	0.000197	0.00128	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000196	0.00127	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000195	0.00126	CcSEcCtD
Canagliflozin—Fatigue—Docetaxel—pancreatic cancer	0.000195	0.00126	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—pancreatic cancer	0.000195	0.00126	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—pancreatic cancer	0.000195	0.00126	CcSEcCtD
Canagliflozin—Nausea—Irinotecan—pancreatic cancer	0.000194	0.00126	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—pancreatic cancer	0.000193	0.00125	CcSEcCtD
Canagliflozin—Nausea—Gemcitabine—pancreatic cancer	0.000189	0.00122	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—pancreatic cancer	0.000187	0.00121	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—pancreatic cancer	0.000187	0.00121	CcSEcCtD
Canagliflozin—Nausea—Fluorouracil—pancreatic cancer	0.000186	0.0012	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000185	0.0012	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—pancreatic cancer	0.00018	0.00117	CcSEcCtD
Canagliflozin—Abdominal pain—Docetaxel—pancreatic cancer	0.000179	0.00116	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—pancreatic cancer	0.000173	0.00112	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—pancreatic cancer	0.000173	0.00112	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—pancreatic cancer	0.000168	0.00108	CcSEcCtD
Canagliflozin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000167	0.00108	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—pancreatic cancer	0.000164	0.00106	CcSEcCtD
Canagliflozin—Asthenia—Docetaxel—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—pancreatic cancer	0.00016	0.00103	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000158	0.00102	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—pancreatic cancer	0.000156	0.00101	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—pancreatic cancer	0.000155	0.001	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000152	0.000983	CcSEcCtD
Canagliflozin—Infection—Epirubicin—pancreatic cancer	0.000152	0.00098	CcSEcCtD
Canagliflozin—Shock—Epirubicin—pancreatic cancer	0.00015	0.00097	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—pancreatic cancer	0.00015	0.000969	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—pancreatic cancer	0.00015	0.000967	CcSEcCtD
Canagliflozin—Dizziness—Docetaxel—pancreatic cancer	0.00015	0.000967	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—pancreatic cancer	0.000148	0.000958	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000146	0.000946	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—pancreatic cancer	0.000144	0.000931	CcSEcCtD
Canagliflozin—Rash—Docetaxel—pancreatic cancer	0.000143	0.000922	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—pancreatic cancer	0.000143	0.000922	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—pancreatic cancer	0.000142	0.000921	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—pancreatic cancer	0.00014	0.000907	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—pancreatic cancer	0.000139	0.000898	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000138	0.000895	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—pancreatic cancer	0.000137	0.000887	CcSEcCtD
Canagliflozin—Nausea—Docetaxel—pancreatic cancer	0.000134	0.000869	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—pancreatic cancer	0.000132	0.000853	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000132	0.000852	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—pancreatic cancer	0.000132	0.00085	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—pancreatic cancer	0.00013	0.000844	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000125	0.000807	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000122	0.000788	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—pancreatic cancer	0.000122	0.000787	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—pancreatic cancer	0.000121	0.000784	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—pancreatic cancer	0.000121	0.00078	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—pancreatic cancer	0.000121	0.00078	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000115	0.000746	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—pancreatic cancer	0.000112	0.000727	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—pancreatic cancer	0.000112	0.000725	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—pancreatic cancer	0.000112	0.000721	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—pancreatic cancer	0.000109	0.000708	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—pancreatic cancer	0.000108	0.000698	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000104	0.000672	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—pancreatic cancer	0.000101	0.000655	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—pancreatic cancer	0.000101	0.000652	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—pancreatic cancer	9.99e-05	0.000646	CcSEcCtD
Canagliflozin—Rash—Epirubicin—pancreatic cancer	9.62e-05	0.000622	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—pancreatic cancer	9.61e-05	0.000621	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—pancreatic cancer	9.33e-05	0.000604	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—pancreatic cancer	9.06e-05	0.000586	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—pancreatic cancer	8.9e-05	0.000575	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—pancreatic cancer	8.89e-05	0.000575	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—pancreatic cancer	8.38e-05	0.000542	CcSEcCtD
Canagliflozin—SLC5A2—Disease—HES1—pancreatic cancer	7.8e-05	0.0015	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—EGF—pancreatic cancer	7.7e-05	0.00148	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—STK11—pancreatic cancer	7.64e-05	0.00147	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—STK11—pancreatic cancer	7.64e-05	0.00147	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—pancreatic cancer	7.5e-05	0.00145	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	7.41e-05	0.00143	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—EGF—pancreatic cancer	7.33e-05	0.00141	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	7.32e-05	0.00141	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	6.88e-05	0.00133	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TERT—pancreatic cancer	6.84e-05	0.00132	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TERT—pancreatic cancer	6.84e-05	0.00132	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TYMS—pancreatic cancer	6.57e-05	0.00127	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TYMS—pancreatic cancer	6.57e-05	0.00127	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CD44—pancreatic cancer	6.55e-05	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HIF1A—pancreatic cancer	6.54e-05	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HIF1A—pancreatic cancer	6.54e-05	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TSC2—pancreatic cancer	6.52e-05	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TSC2—pancreatic cancer	6.52e-05	0.00126	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	6.52e-05	0.00126	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	6.4e-05	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APOE—pancreatic cancer	6.38e-05	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APOE—pancreatic cancer	6.38e-05	0.00123	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	6.29e-05	0.00121	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GCG—pancreatic cancer	6.28e-05	0.00121	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—STK11—pancreatic cancer	5.9e-05	0.00114	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOTCH1—pancreatic cancer	5.89e-05	0.00114	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOTCH1—pancreatic cancer	5.89e-05	0.00114	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—pancreatic cancer	5.72e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGF—pancreatic cancer	5.7e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGF—pancreatic cancer	5.7e-05	0.0011	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	5.56e-05	0.00107	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA5—pancreatic cancer	5.53e-05	0.00107	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PRSS1—pancreatic cancer	5.49e-05	0.00106	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—pancreatic cancer	5.48e-05	0.00106	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	5.39e-05	0.00104	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—APOE—pancreatic cancer	5.35e-05	0.00103	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—APOE—pancreatic cancer	5.35e-05	0.00103	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PPP2R5B—pancreatic cancer	5.22e-05	0.00101	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TYMS—pancreatic cancer	5.08e-05	0.000979	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL8—pancreatic cancer	5.08e-05	0.000979	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CD—pancreatic cancer	5.07e-05	0.000977	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CD—pancreatic cancer	5.07e-05	0.000977	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB1—pancreatic cancer	5.05e-05	0.000973	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFB1—pancreatic cancer	4.92e-05	0.000949	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	4.87e-05	0.000939	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CASP3—pancreatic cancer	4.86e-05	0.000937	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CG—pancreatic cancer	4.83e-05	0.00093	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CG—pancreatic cancer	4.83e-05	0.00093	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—pancreatic cancer	4.79e-05	0.000924	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	4.76e-05	0.000918	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ARG2—pancreatic cancer	4.76e-05	0.000917	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	4.72e-05	0.00091	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—pancreatic cancer	4.66e-05	0.000898	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPARG—pancreatic cancer	4.66e-05	0.000898	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPARG—pancreatic cancer	4.66e-05	0.000898	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—pancreatic cancer	4.66e-05	0.000898	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	4.63e-05	0.000894	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—pancreatic cancer	4.44e-05	0.000856	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CB—pancreatic cancer	4.42e-05	0.000851	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CB—pancreatic cancer	4.42e-05	0.000851	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—pancreatic cancer	4.37e-05	0.000843	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—pancreatic cancer	4.37e-05	0.000843	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB1—pancreatic cancer	4.27e-05	0.000824	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CD—pancreatic cancer	4.24e-05	0.000818	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CD—pancreatic cancer	4.24e-05	0.000818	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMP—pancreatic cancer	4.16e-05	0.000802	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—APOE—pancreatic cancer	4.13e-05	0.000796	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—pancreatic cancer	4.12e-05	0.000795	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—pancreatic cancer	4.1e-05	0.000791	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—pancreatic cancer	4.07e-05	0.000785	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CTNNB1—pancreatic cancer	3.91e-05	0.000755	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CTNNB1—pancreatic cancer	3.91e-05	0.000755	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTEN—pancreatic cancer	3.82e-05	0.000736	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTEN—pancreatic cancer	3.82e-05	0.000736	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—pancreatic cancer	3.78e-05	0.00073	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CG—pancreatic cancer	3.73e-05	0.000718	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—pancreatic cancer	3.7e-05	0.000713	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CB—pancreatic cancer	3.7e-05	0.000713	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CB—pancreatic cancer	3.7e-05	0.000713	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—pancreatic cancer	3.66e-05	0.000706	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—pancreatic cancer	3.66e-05	0.000706	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—pancreatic cancer	3.6e-05	0.000693	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SRC—pancreatic cancer	3.54e-05	0.000682	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SRC—pancreatic cancer	3.54e-05	0.000682	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—pancreatic cancer	3.53e-05	0.000681	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	3.51e-05	0.000677	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	3.5e-05	0.000674	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	3.45e-05	0.000666	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.43e-05	0.000661	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	3.41e-05	0.000658	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—pancreatic cancer	3.41e-05	0.000658	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—pancreatic cancer	3.41e-05	0.000658	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NRAS—pancreatic cancer	3.4e-05	0.000656	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NRAS—pancreatic cancer	3.4e-05	0.000656	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	3.36e-05	0.000648	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GLP1R—pancreatic cancer	3.35e-05	0.000646	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—DPYD—pancreatic cancer	3.3e-05	0.000636	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CD—pancreatic cancer	3.28e-05	0.000632	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—pancreatic cancer	3.2e-05	0.000616	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—pancreatic cancer	3.2e-05	0.000616	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—pancreatic cancer	3.17e-05	0.000611	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—pancreatic cancer	3.17e-05	0.000611	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—pancreatic cancer	3.16e-05	0.00061	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—pancreatic cancer	3.16e-05	0.00061	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CD44—pancreatic cancer	3.13e-05	0.000603	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC2A2—pancreatic cancer	3.13e-05	0.000603	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—pancreatic cancer	3.1e-05	0.000598	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—pancreatic cancer	3.1e-05	0.000598	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.1e-05	0.000597	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	3.06e-05	0.000591	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	3.04e-05	0.000586	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	3.04e-05	0.000586	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA1—pancreatic cancer	3.03e-05	0.000584	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.99e-05	0.000576	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—pancreatic cancer	2.93e-05	0.000565	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—pancreatic cancer	2.93e-05	0.000565	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PRSS1—pancreatic cancer	2.87e-05	0.000554	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CB—pancreatic cancer	2.85e-05	0.00055	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—pancreatic cancer	2.83e-05	0.000545	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA2—pancreatic cancer	2.82e-05	0.000544	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.72e-05	0.000525	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—pancreatic cancer	2.69e-05	0.000519	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—pancreatic cancer	2.69e-05	0.000519	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	2.65e-05	0.00051	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	2.58e-05	0.000498	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PRSS1—pancreatic cancer	2.52e-05	0.000485	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ARG2—pancreatic cancer	2.49e-05	0.00048	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—pancreatic cancer	2.49e-05	0.00048	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—pancreatic cancer	2.49e-05	0.00048	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—pancreatic cancer	2.47e-05	0.000476	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD44—pancreatic cancer	2.42e-05	0.000467	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	2.4e-05	0.000462	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.37e-05	0.000457	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.35e-05	0.000453	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	2.33e-05	0.00045	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GCG—pancreatic cancer	2.32e-05	0.000448	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	2.31e-05	0.000446	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—pancreatic cancer	2.25e-05	0.000435	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—pancreatic cancer	2.25e-05	0.000435	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	2.25e-05	0.000434	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—pancreatic cancer	2.2e-05	0.000424	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—pancreatic cancer	2.2e-05	0.000424	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—STK11—pancreatic cancer	2.18e-05	0.000421	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ARG2—pancreatic cancer	2.18e-05	0.000421	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMP—pancreatic cancer	2.18e-05	0.00042	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	2.12e-05	0.000409	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	2.09e-05	0.000403	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	2.07e-05	0.000398	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.05e-05	0.000395	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	2.03e-05	0.000392	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAU—pancreatic cancer	2e-05	0.000386	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMP—pancreatic cancer	1.91e-05	0.000368	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	1.9e-05	0.000366	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMS—pancreatic cancer	1.88e-05	0.000362	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.87e-05	0.000361	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.87e-05	0.00036	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—pancreatic cancer	1.84e-05	0.000355	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—pancreatic cancer	1.84e-05	0.000355	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.83e-05	0.000353	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.8e-05	0.000346	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—pancreatic cancer	1.78e-05	0.000343	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EGF—pancreatic cancer	1.76e-05	0.000339	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GLP1R—pancreatic cancer	1.75e-05	0.000338	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.74e-05	0.000336	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—pancreatic cancer	1.74e-05	0.000336	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.73e-05	0.000333	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—DPYD—pancreatic cancer	1.73e-05	0.000333	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A2—pancreatic cancer	1.64e-05	0.000316	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.62e-05	0.000313	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	1.61e-05	0.000311	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.59e-05	0.000306	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—pancreatic cancer	1.57e-05	0.000302	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.56e-05	0.000302	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.55e-05	0.000299	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GLP1R—pancreatic cancer	1.54e-05	0.000296	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.54e-05	0.000296	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—pancreatic cancer	1.53e-05	0.000295	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—DPYD—pancreatic cancer	1.51e-05	0.000292	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.45e-05	0.000279	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A2—pancreatic cancer	1.44e-05	0.000277	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.43e-05	0.000275	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—pancreatic cancer	1.42e-05	0.000274	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—pancreatic cancer	1.38e-05	0.000266	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—pancreatic cancer	1.36e-05	0.000263	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.34e-05	0.000259	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—pancreatic cancer	1.33e-05	0.000257	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	1.32e-05	0.000254	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.3e-05	0.00025	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD44—pancreatic cancer	1.27e-05	0.000245	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.24e-05	0.00024	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.23e-05	0.000237	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCG—pancreatic cancer	1.22e-05	0.000234	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—pancreatic cancer	1.21e-05	0.000234	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.18e-05	0.000227	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—STK11—pancreatic cancer	1.14e-05	0.00022	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD44—pancreatic cancer	1.11e-05	0.000214	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—pancreatic cancer	1.09e-05	0.000211	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.07e-05	0.000207	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCG—pancreatic cancer	1.07e-05	0.000205	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—pancreatic cancer	1.06e-05	0.000205	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—pancreatic cancer	1.06e-05	0.000204	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—pancreatic cancer	1.05e-05	0.000203	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—pancreatic cancer	1.05e-05	0.000202	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—STK11—pancreatic cancer	1e-05	0.000193	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—pancreatic cancer	9.84e-06	0.00019	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—pancreatic cancer	9.77e-06	0.000188	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GLP1R—pancreatic cancer	9.47e-06	0.000183	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DPYD—pancreatic cancer	9.32e-06	0.00018	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—pancreatic cancer	9.13e-06	0.000176	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—pancreatic cancer	9.05e-06	0.000175	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	8.84e-06	0.00017	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—pancreatic cancer	8.62e-06	0.000166	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—pancreatic cancer	8.32e-06	0.00016	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—pancreatic cancer	8.05e-06	0.000155	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—pancreatic cancer	8e-06	0.000154	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—pancreatic cancer	7.7e-06	0.000148	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.57e-06	0.000146	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—pancreatic cancer	7.22e-06	0.000139	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—pancreatic cancer	7.01e-06	0.000135	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—pancreatic cancer	6.97e-06	0.000134	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD44—pancreatic cancer	6.85e-06	0.000132	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—pancreatic cancer	6.79e-06	0.000131	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCG—pancreatic cancer	6.57e-06	0.000127	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	6.44e-06	0.000124	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—pancreatic cancer	6.35e-06	0.000122	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—pancreatic cancer	6.33e-06	0.000122	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—STK11—pancreatic cancer	6.17e-06	0.000119	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—pancreatic cancer	6.11e-06	0.000118	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.56e-06	0.000107	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—pancreatic cancer	5.53e-06	0.000107	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—pancreatic cancer	5.48e-06	0.000106	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—pancreatic cancer	5.31e-06	0.000102	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—pancreatic cancer	5.26e-06	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.85e-06	9.35e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.8e-06	9.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—pancreatic cancer	4.78e-06	9.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—pancreatic cancer	4.32e-06	8.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—pancreatic cancer	4.19e-06	8.08e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.9e-06	7.51e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.76e-06	7.25e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.43e-06	6.61e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—pancreatic cancer	3.37e-06	6.5e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.99e-06	5.76e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.96e-06	5.71e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.95e-06	5.7e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—pancreatic cancer	2.75e-06	5.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.58e-06	4.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—pancreatic cancer	2.41e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.82e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.49e-06	2.87e-05	CbGpPWpGaD
